These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 15652330)

  • 1. Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
    Gonçalves GS; Fernandes AP; Souza RC; Cardoso JE; de Oliveira-Silva F; Maciel FC; Rabello A; Ferreira LA
    Acta Trop; 2005 Feb; 93(2):161-7. PubMed ID: 15652330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
    Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
    J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil.
    Romero GA; de la Glória Orge Orge M; de Farias Guerra MV; Paes MG; de Oliveira Macêdo V; de Carvalho EM
    Acta Trop; 2005 Jan; 93(1):49-56. PubMed ID: 15589797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.
    Grogl M; Schuster BG; Ellis WY; Berman JD
    J Parasitol; 1999 Apr; 85(2):354-9. PubMed ID: 10219319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
    de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
    J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis.
    Carneiro G; Santos DC; Oliveira MC; Fernandes AP; Ferreira LS; Ramaldes GA; Nunan EA; Ferreira LA
    J Liposome Res; 2010 Mar; 20(1):16-23. PubMed ID: 19530897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis.
    Mussi SV; Fernandes AP; Ferreira LA
    Parasitol Res; 2007 May; 100(6):1221-6. PubMed ID: 17206508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.
    Zauli-Nascimento RC; Miguel DC; Yokoyama-Yasunaka JK; Pereira LI; Pelli de Oliveira MA; Ribeiro-Dias F; Dorta ML; Uliana SR
    Trop Med Int Health; 2010 Jan; 15(1):68-76. PubMed ID: 19874570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
    Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
    J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
    Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
    Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
    Arevalo J; Ramirez L; Adaui V; Zimic M; Tulliano G; Miranda-Verástegui C; Lazo M; Loayza-Muro R; De Doncker S; Maurer A; Chappuis F; Dujardin JC; Llanos-Cuentas A
    J Infect Dis; 2007 Jun; 195(12):1846-51. PubMed ID: 17492601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.
    Teva A; Porrozzi R; Oliveira-Neto MP; Grimaldi GJ
    J Parasitol; 2005 Aug; 91(4):976-8. PubMed ID: 17089782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.
    Llanos-Cuentas A; Tulliano G; Araujo-Castillo R; Miranda-Verastegui C; Santamaria-Castrellon G; Ramirez L; Lazo M; De Doncker S; Boelaert M; Robays J; Dujardin JC; Arevalo J; Chappuis F
    Clin Infect Dis; 2008 Jan; 46(2):223-31. PubMed ID: 18171254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
    Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
    Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antileishmanial activity of azithromycin against Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi.
    de Oliveira-Silva F; de Morais-Teixeira E; Rabello A
    Am J Trop Med Hyg; 2008 May; 78(5):745-9. PubMed ID: 18458308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
    Krolewiecki AJ; Romero HD; Cajal SP; Abraham D; Mimori T; Matsumoto T; Juarez M; Taranto NJ
    Am J Trop Med Hyg; 2007 Oct; 77(4):640-6. PubMed ID: 17978064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
    Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC
    Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions.
    Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A
    J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis.
    Solomon M; Baum S; Barzilai A; Scope A; Trau H; Schwartz E
    J Am Acad Dermatol; 2007 Apr; 56(4):612-6. PubMed ID: 17276541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
    Soto J; Hernandez N; Mejia H; Grogl M; Berman J
    Clin Infect Dis; 1995 Jan; 20(1):47-51. PubMed ID: 7727669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.